Suppr超能文献

用于药物成瘾的新型药物的研发。一种非洲灌木的传承。

Development of novel medications for drug addiction. The legacy of an African shrub.

作者信息

Glick S D, Maisonneuve I M

机构信息

Department of Pharmacology and Neuroscience, Albany Medical College, New York 12208, USA.

出版信息

Ann N Y Acad Sci. 2000;909:88-103. doi: 10.1111/j.1749-6632.2000.tb06677.x.

Abstract

Ibogaine, one of several alkaloids found in the root bark of the African shrub Tabernanthe iboga, has been claimed to be effective in treating multiple forms of drug abuse. Problems associated with side effects of ibogaine have spawned a search for more effective and safer structural derivatives. 18-Methoxycoronaridine (18-MC), a novel iboga alkaloid congener, appears to have substantial potential for broad use as an anti-addictive therapy. Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; unlike ibogaine, 18-MC does not affect responding for a non-drug reinforcer (water). Ibogaine and 18-MC appear to reduce the reinforcing efficacies, rather than the potencies, of drugs of abuse. Both ibogaine and 18-MC decreases extracellular levels of dopamine in the nucleus accumbens while only ibogaine increases serotonin levels in this brain region. Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the accumbens; only ibogaine enhances cocaine-induced increases in dopamine levels. Ibogaine produces whole body tremors and, at high doses (at least 100 mg/kg), cerebellar damage; 18-MC does not produce these effects. Ibogaine, but not 18-MC, causes bradycardia at high doses. Ibogaine and its metabolite noribogaine have low microM affinities for kappa and mu opioid receptors, NMDA receptors, 5HT-3 receptors, sigma-2 sites, sodium channels and the serotonin transporter. 18-MC has low microM affinities at all three opioid receptors and at 5HT-3 receptors but much lower or no affinities for NMDA and sigma-2 receptors, sodium channels, and the 5HT transporter. Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 18-MC also has (+) and (-) enantiomers, both of which are active. Considered together, all of the data indicate that 18-MC should be safer than ibogaine and at least as efficacious as an anti-addictive medication.

摘要

伊博格碱是在非洲灌木伊博格(Tabernanthe iboga)的根皮中发现的几种生物碱之一,据称对治疗多种形式的药物滥用有效。与伊博格碱副作用相关的问题促使人们寻找更有效、更安全的结构衍生物。18-甲氧基柯诺里定(18-MC)是一种新型的伊博格生物碱同系物,似乎具有作为抗成瘾疗法广泛应用的巨大潜力。与伊博格碱(40毫克/千克)一样,18-MC(40毫克/千克)可减少大鼠静脉注射吗啡和可卡因以及口服乙醇和尼古丁的自我给药;与伊博格碱不同的是,18-MC不影响对非药物强化物(水)的反应。伊博格碱和18-MC似乎降低了滥用药物的强化效力,而非效力。伊博格碱和18-MC均降低伏隔核中多巴胺的细胞外水平,而只有伊博格碱会增加该脑区的血清素水平。伊博格碱和18-MC均阻断伏隔核中吗啡诱导和尼古丁诱导的多巴胺释放;只有伊博格碱会增强可卡因诱导的多巴胺水平升高。伊博格碱会引起全身震颤,高剂量(至少100毫克/千克)时会导致小脑损伤;18-MC不会产生这些影响。高剂量时,伊博格碱而非18-MC会导致心动过缓。伊博格碱及其代谢产物去甲伊博格碱对κ和μ阿片受体、NMDA受体、5HT-3受体、σ-2位点、钠通道和血清素转运体具有低微摩尔亲和力。18-MC对所有三种阿片受体和5HT-3受体具有低微摩尔亲和力,但对NMDA和σ-2受体、钠通道和5HT转运体的亲和力低得多或无亲和力。18-MC和伊博格碱都被隔离在脂肪中,与伊博格碱一样,18-MC可能有一种活性代谢产物。18-MC也有(+)和(-)对映体,两者都有活性。综合考虑,所有数据表明18-MC应该比伊博格碱更安全,并且作为抗成瘾药物至少同样有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验